Boston Scientific
| Company type | Public |
|---|---|
| ISIN | US1011371077 |
| Industry | Medical device |
| Founded | June 29, 1979 in Watertown, Massachusetts |
| Founders | |
| Headquarters | Marlborough, Massachusetts, U.S. |
Key people | |
| Revenue | US$20.1 billion (2025) |
| US$3.61 billion (2025) | |
| US$2.90 billion (2025) | |
| Total assets | US$43.7 billion (2025) |
| Total equity | US$24.2 billion (2025) |
Number of employees | 59,000 (2025) |
| Website | bostonscientific |
| Footnotes / references | |
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator (ICD) called the EMBLEM subcutaneous implantable defibrillator (S-ICD).
Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen.
BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.